SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rudy Saucillo who wrote (1265)3/10/1998 11:25:00 AM
From: Bhag Karamchandani  Read Replies (1) of 2173
 
'An effective glucose control drug should,ideally, drive insulin requirements down; not be overwhelmed by it.'

Your statement presupposes that pramlintide is a glucose control protein. It can be argued that it may prove to be the essential companion protein - necessary for better controlling the long term effects of diabetes.

I am neither a shareholder nor an expert but simply one who is waiting for a better treatment option for Type I diabetes - rate of incidence of Type I diabetes is growing at phenomenal rates according to Juvenile Diabetes Foundation.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News